1. a b Tian J1, et al. Antidepressant-like activity of adhyperforin, a novel constituent of Hypericum perforatum LSci Rep. (2014)
  2. ^ Brockmöller J1, et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humansPharmacopsychiatry. (1997)
  3. a b c d Kerb R1, et al. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericinAntimicrob Agents Chemother. (1996)
  4. a b c d Treiber K1, et al. Hyperforin activates nonselective cation channels (NSCCs)Br J Pharmacol. (2005)
  5. ^ Yang B1, Samson WK, Ferguson AV. Excitatory effects of orexin-A on nucleus tractus solitarius neurons are mediated by phospholipase C and protein kinase CJ Neurosci. (2003)
  6. ^ Leuner K1, et al. Hyperforin–a key constituent of St. John’s wort specifically activates TRPC6 channelsFASEB J. (2007)
  7. a b Leuner K1, et al. Hyperforin modulates dendritic spine morphology in hippocampal pyramidal neurons by activating Ca(2+) -permeable TRPC6 channelsHippocampus. (2013)
  8. a b c d Gobbi M1, et al. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortexNaunyn Schmiedebergs Arch Pharmacol. (1999)
  9. a b c d Singer A1, Wonnemann M, Müller WE. Hyperforin, a major antidepressant constituent of St. John’s Wort, inhibits serotonin uptake by elevating free intracellular Na+1J Pharmacol Exp Ther. (1999)
  10. ^ Chatterjee SS1, et al. Hyperforin as a possible antidepressant component of hypericum extractsLife Sci. (1998)
  11. a b c d e f g h i Yoshitake T1, et al. Hypericum perforatum L (St John’s wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortexBr J Pharmacol. (2004)
  12. a b c d e f Russo E1, et al. Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactionsPhytother Res. (2014)
  13. a b Staffeldt B1, et al. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteersJ Geriatr Psychiatry Neurol. (1994)
  14. a b c Biber A1, et al. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteersPharmacopsychiatry. (1998)
  15. ^ Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John’s wort drug interactions.Curr Drug Metab. (2008)
  16. ^ Goodwin B, et al. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor.Mol Pharmacol. (2001)
  17. ^ Chen Y, et al. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor.J Pharmacol Exp Ther. (2004)
  18. ^ Rahimi R, Abdollahi M. An update on the ability of St. John’s wort to affect the metabolism of other drugs.Expert Opin Drug Metab Toxicol. (2012)
  19. ^ Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression.J Pharmacol Exp Ther. (2000)
  20. ^ Bauer S, et al. Differential effects of Saint John’s Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6beta-hydroxycortisol in healthy volunteers.Eur J Clin Pharmacol. (2002)
  21. ^ Wang LS, et al. St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.Clin Pharmacol Ther. (2004)
  22. ^ Smith P, et al. The influence of St. John’s wort on the pharmacokinetics and protein binding of imatinib mesylate.Pharmacotherapy. (2004)
  23. ^ Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein.Drug Metab Rev. (2004)
  24. ^ Wang Z, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity.Clin Pharmacol Ther. (2001)
  25. ^ Wenk M, Todesco L, Krähenbühl S. Effect of St John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females.Br J Clin Pharmacol. (2004)
  26. ^ Imai H, et al. The recovery time-course of CYP3A after induction by St John’s wort administrationBr J Clin Pharmacol. (2008)
  27. a b Chen XW, et al. Clinical herbal interactions with conventional drugs: from molecules to maladies.Curr Med Chem. (2011)
  28. ^ Morimoto T, et al. Effect of St. John’s wort on the pharmacokinetics of theophylline in healthy volunteers.J Clin Pharmacol. (2004)
  29. ^ Jiang X, et al. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.Br J Clin Pharmacol. (2004)
  30. ^ Schulz V. Safety of St. John’s Wort extract compared to synthetic antidepressants.Phytomedicine. (2006)
  31. ^ Wang XD, et al. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study.J Chromatogr B Analyt Technol Biomed Life Sci. (2007)
  32. ^ Tannergren C, et al. St John’s wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism.Clin Pharmacol Ther. (2004)
  33. a b Sugimoto K, et al. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin.Clin Pharmacol Ther. (2001)
  34. ^ Eggertsen R, Andreasson A, Andrén L. Effects of treatment with a commercially available St John’s Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin.Scand J Prim Health Care. (2007)
  35. ^ Wang LS, et al. The influence of St John’s Wort on CYP2C19 activity with respect to genotype.J Clin Pharmacol. (2004)
  36. ^ Mannel M. Drug interactions with St John’s wort : mechanisms and clinical implications.Drug Saf. (2004)
  37. ^ Hall SD, et al. The interaction between St John’s wort and an oral contraceptive.Clin Pharmacol Ther. (2003)
  38. ^ Di YM, et al. Clinical drugs that interact with St. John’s wort and implication in drug development.Curr Pharm Des. (2008)
  39. ^ Bauer S, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John’s wort in renal transplant patients.Br J Clin Pharmacol. (2003)
  40. ^ Mathijssen RH, et al. Effects of St. John’s wort on irinotecan metabolism.J Natl Cancer Inst. (2002)
  41. ^ Zhou S, et al. Pharmacokinetic interactions of drugs with St John’s wort.J Psychopharmacol. (2004)
  42. ^ Jakobs D1, et al. Downregulation of β1 -adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside from St John’s wortJ Pharm Pharmacol. (2013)
  43. ^ Prenner L1, et al. Reduction of high-affinity beta2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopyBiochemistry. (2007)
  44. a b Simbrey K1, Winterhoff H, Butterweck V. Extracts of St. John’s wort and various constituents affect beta-adrenergic binding in rat frontal cortexLife Sci. (2004)
  45. ^ De Marchis GM1, et al. Vitamin E reduces antidepressant-related beta-adrenoceptor down-regulation in cultured cells. Comparable effects on St. John’s wort and tricyclic antidepressant treatmentPlanta Med. (2006)
  46. a b Müller WE1, et al. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activityPharmacopsychiatry. (1997)
  47. a b c Müller WE1, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extractPharmacopsychiatry. (1998)
  48. ^ Müller WE. Current St John’s wort research from mode of action to clinical efficacyPharmacol Res. (2003)
  49. ^ Carboni E1, et al. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminalsJ Neurochem. (1990)
  50. ^ Mollenhauer HH1, Morré DJ, Rowe LD. Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicityBiochim Biophys Acta. (1990)
  51. ^ Suzuki O, et al. Inhibition of monoamine oxidase by hypericinPlanta Med. (1984)
  52. ^ Bladt S1, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extractJ Geriatr Psychiatry Neurol. (1994)
  53. a b c Thiede HM1, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericinJ Geriatr Psychiatry Neurol. (1994)
  54. a b c d Linde K, Berner MM, Kriston L. St John’s wort for major depressionCochrane Database Syst Rev. (2008)
  55. ^ Linde K, et al. St John’s wort for depression: meta-analysis of randomised controlled trialsBr J Psychiatry. (2005)
  56. a b Gelenberg AJ, et al. The effectiveness of St. John’s Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medicationJ Clin Psychiatry. (2004)
  57. ^ Brenner R, Madhusoodanan S, Pawlowska M. Efficacy of continuation treatment with hypericum perforatum in depressionJ Clin Psychiatry. (2002)
  58. a b Fava M, et al. A Double-blind, randomized trial of St John’s wort, fluoxetine, and placebo in major depressive disorderJ Clin Psychopharmacol. (2005)
  59. a b Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trialJAMA. (2002)
  60. ^ Kasper S, et al. Superior efficacy of St John’s wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial {ISRCTN77277298}BMC Med. (2006)
  61. ^ Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study.
  62. ^ Laakmann G, et al. St. John’s wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacyPharmacopsychiatry. (1998)
  63. ^ Effectiveness of St John’s Wort in Major Depression.
  64. ^ Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trialPharmacopsychiatry. (2001)
  65. ^ Hänsgen KD, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160J Geriatr Psychiatry Neurol. (1994)
  66. ^ The Ham D6 is more homogenous and as sensitive as the Ham D17.
  67. ^ Lecrubier Y, et al. Efficacy of St. John’s wort extract WS 5570 in major depression: a double-blind, placebo-controlled trialAm J Psychiatry. (2002)
  68. ^ Uebelhack R, et al. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trialAdv Ther. (2004)
  69. ^ Schrader E. Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depressionInt Clin Psychopharmacol. (2000)
  70. ^ Behnke K, et al. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depressionAdv Ther. (2002)
  71. ^ Bjerkenstedt L, et al. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatientsEur Arch Psychiatry Clin Neurosci. (2005)
  72. ^ Brenner R, et al. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot studyClin Ther. (2000)
  73. ^ Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertralinePharmacopsychiatry. (2005)
  74. ^ Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled studyPharmacopsychiatry. (2006)
  75. ^ St John’s wort or sertraline? Randomized controlled trial in primary care.
  76. ^ Harrer G, Hübner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind studyJ Geriatr Psychiatry Neurol. (1994)
  77. ^ Harrer G, et al. Comparison of equivalence between the St. John’s wort extract LoHyp-57 and fluoxetineArzneimittelforschung. (1999)
  78. ^ Vitiello B, et al. Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression TrialJ Clin Psychopharmacol. (2005)
  79. ^ Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis.
  80. ^ Moreno RA, et al. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sampleRev Bras Psiquiatr. (2006)
  81. ^ Anghelescu IG, et al. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter studyPharmacopsychiatry. (2006)
  82. a b Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeksBMJ. (1999)
  83. ^ Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial.
  84. ^ Vorbach EU, Arnoldt KH, Hübner WD. Efficacy and tolerability of St. John’s wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10Pharmacopsychiatry. (1997)
  85. ^ Wheatley D. LI 160, an extract of St. John’s wort, versus amitriptyline in mildly to moderately depressed outpatients–a controlled 6-week clinical trialPharmacopsychiatry. (1997)